Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × OTHER_GOV × Probiotics × Clear all

Phase

Phase NA 2 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Psoriasis Vulgaris 1

Interventions

Cyclophosphamide 4 Cisplatin 3 pembrolizumab 2 fludarabine 2 apatinib 2 XELOX 2 S 1 (combination) 2 Paclitaxel 2 Oxaliplatin 2 Nivolumab 2 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2 Irinotecan 2 Injections 2 Gemcitabine 2 Fulvestrant 2 Epirubicin 2 Drug Therapy 2 titanium silicide 1 tislelizumab 1 surufatinib 1 sintilimab 1 pegfilgrastim 1 nimotuzumab 1 ipatasertib 1 ferumoxides 1 famitinib 1 eribulin 1 dalpiciclib 1 dactolisib 1 capivasertib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05254249 2022-02-24

Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris

Dr. Soetomo General Hospital

Phase 1/2 Unknown

Psoriasis Vulgaris

Data powered by HemOnc (CC BY 4.0) Colophon ⚡